Last reviewed · How we verify

Botox placebo (normal saline)

Allergan · Phase 3 active Small molecule Under review

Botox placebo (normal saline) is a Small molecule drug developed by Allergan. It is currently in Phase 3 development for Placebo control in Botox clinical trials (Phase 3).

Normal saline is an inert placebo with no active pharmacological mechanism.

Botox placebo, also known as preservative-free saline, has been used in clinical trials to study its effects on various conditions, including glabellar rhytides, chronic migraine, and neurogenic bladder dysfunction. The mechanism of action of Botox placebo is unknown, as indicated by ChEMBL.

Likelihood of approval
58.3% vs 58.3% industry baseline
If approved by FDA: likely 2028–2030
Steps remaining: NDA/BLA submission
Confidence: High
Why this estimate
  • Baseline phase 3 → approval rate +58.3pp
    Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Predicted approval windows by jurisdiction (conditional on FDA approval)
Regulator Country Likely year Lag vs FDA
FDA US 2028–2030 —
EMA EU 2029–2031 +0.7 yr
MHRA GB 2029–2031 +0.7 yr
Health Canada CA 2029–2032 +0.9 yr
TGA AU 2029–2032 +1.2 yr
PMDA JP 2029–2032 +1.5 yr
NMPA CN 2030–2033 +2.3 yr
MFDS KR 2029–2032 +1.4 yr
CDSCO IN 2029–2033 +1.8 yr
ANVISA BR 2030–2033 +2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic nameBotox placebo (normal saline)
SponsorAllergan
ModalitySmall molecule
PhasePhase 3

Mechanism of action

Normal saline (0.9% sodium chloride solution) is a physiologically balanced salt solution used as a control comparator in clinical trials. It has no therapeutic mechanism of action and serves solely as a placebo to establish baseline efficacy and safety of the active investigational drug through blinded comparison.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Botox placebo (normal saline)

What is Botox placebo (normal saline)?

Botox placebo (normal saline) is a Small molecule drug developed by Allergan, indicated for Placebo control in Botox clinical trials (Phase 3).

How does Botox placebo (normal saline) work?

Normal saline is an inert placebo with no active pharmacological mechanism.

What is Botox placebo (normal saline) used for?

Botox placebo (normal saline) is indicated for Placebo control in Botox clinical trials (Phase 3).

Who makes Botox placebo (normal saline)?

Botox placebo (normal saline) is developed by Allergan (see full Allergan pipeline at /company/allergan).

What development phase is Botox placebo (normal saline) in?

Botox placebo (normal saline) is in Phase 3.

What are the side effects of Botox placebo (normal saline)?

Common side effects of Botox placebo (normal saline) include Injection site reactions (expected from needle insertion only).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing